Transcript NEWMEDS - GABO:mi

NEWMEDS
Novel MEthods leading to
NeW MEdications in Depression
and Schizophrenia
NEWMEDS – the work leading to these results has received funding from the Innovative Medicines Initiative Joint Undertaking (IMI)
IMI JU: Vision and Objective
Vision
“Creating Biomedical Research & Development Leadership
for Europe to the Benefit of Patients and Society”
Objectives
Support of a faster discovery and development of better
medicines for patients
Enhancement of Europe’s competitiveness by ensuring
that its biopharmaceutical sector remains a dynamic
high-technology sector
2
3
What is NEWMEDS?
NEWMEDS is
an international consortium of scientists that has launched
one of the largest ever research academic-industry
collaboration projects
to find new methods for the development of drugs for
schizophrenia and depression.
4
The Consortium
5
Who are the members in NEWMEDS?
EFPIA companies
H Lundbeck A/S, AstraZeneca AB, Eli Lilly and Company
Ltd, Janssen Pharmaceutica NV, Novartis Pharma AG,
Orion Corporation, Pfizer Limited, F. Hoffmann-La Roche
AG, Institut de Recherches Servier
Universities
King’s College London (UK), Karolinska Institutet
(Sweden), The University of Cambridge (UK), Central
Institute of Mental Health (Germany), CSIC (Spain), The
University of Manchester (UK), Bar Ilan University (Israel)
SME‘s
Psynova Neurotech Ltd (UK), deCODE genetics (Iceland),
GABO:mi (Germany)
6
NEWMEDS Workpackage Leads
7
Who are the key contacts in NEWMEDS?
Coordinator: H Lundbeck A/S, Copenhagen, Dr Tine Bryan
Stensbøl
Leader of the Managing Entity: King’s College London,
London, Prof Shitij Kapur
Project Office: GABO:milliarium mbH & Co. KG, Munich,
Kathrin Stoller
www.newmeds-europe.com
8
What is the intention of NEWMEDS?
NEWMEDS brings together top scientists from academic
institutions with a wide range of expertise, and partners
them with nearly all major biopharmaceutical companies.
The project will focus on developing new animal models
which use brain recording and behavioural tests to
identify innovative and effective drugs for schizophrenia.
The project will develop standardised paradigms,
acquisition and analysis techniques to apply brain
imaging, especially fMRI and PET imaging to drug
development.
9
What is the intention of NEWMEDS?
NEWMEDS will examine how new genetic findings
(duplication and deletion or changes in genes) influence
the response to various drugs and whether this
information can be used to choose the right drug for the
right patient.
Finally, it will try and develop new approaches for shorter
and more efficient trials of new medication – trials that
may require fewer patients and give faster results.
10
Who supports NEWMEDS?
NEWMEDS is funded by the Innovative Medicines Initiative
(IMI), a unique large scale public-private partnership
between the European Union (represented by the
European Commission) and the pharmaceutical industry
(represented by the European Federation of
Pharmaceutical Industries and Associations, EFPIA).
IMI aims to put Europe at the forefront of
biopharmaceutical innovation and to support more
efficient discovery and development of better medicines
for patients.
www.imi.europa.eu
11
Key data for NEWMEDS
Start date:
1 September 2009
Runtime:
5 years
Structure:
11 Workpackages
Clusters:
System based animal models (A)
Translational Technology (B)
Patient Stratification (C)
12
NEWMEDS science in a nutshell
Systems based
animal models
Circuit-based Models
Models/Measures of Cognition
Cross species imaging
A
Innovative
Medicines
C
B
Hu
m
PE
an
fM
RI
-b
Im
as
ed
pr
ed
ov
ne
ed
m
ur
od
oc
im
el
eh
ag
s
m
e
i
s
an
t
ry
al
ys
is
T
ba
s
Tr
a
Te nsl
ch ati
no o n
a
lo
gy l
nt on
tie ati
Pa ific
t
ra
St
ys
wa
h
at
lp
rs
e
v
rs
to
o
c
i
n
ke
r
d
a
e
to
m
Pr
c
ics
i
c
t
i
et
ne
s
om
en
te
ge
ign
g
o
r
s
o
V
e
lP
ac
CN
ld
na
rm
ia
r
o
a
i
t
t
l
Ph
sla
ica
n
n
i
a
cl
Tr
el
v
No
13